Symptom and Quality of Life Improvement in LUX-Lung 6: An Open-Label Phase III Study of Afatinib Versus Cisplatin/Gemcitabine in Asian Patients With EGFR Mutation-Positive Advanced Non-small-cell Lung Cancer (Q38453565)

From Wikidata
Jump to navigation Jump to search
The printable version is no longer supported and may have rendering errors. Please update your browser bookmarks and please use the default browser print function instead.
scientific article published on June 2015
Language Label Description Also known as
English
Symptom and Quality of Life Improvement in LUX-Lung 6: An Open-Label Phase III Study of Afatinib Versus Cisplatin/Gemcitabine in Asian Patients With EGFR Mutation-Positive Advanced Non-small-cell Lung Cancer
scientific article published on June 2015

    Statements

    title
    Symptom and Quality of Life Improvement in LUX-Lung 6: An Open-Label Phase III Study of Afatinib Versus Cisplatin/Gemcitabine in Asian Patients With EGFR Mutation-Positive Advanced Non-small-cell Lung Cancer (English)
    1 reference
    stated in
    Europe PubMed Central
    PubMed publication ID
    25933111
    retrieved
    3 September 2017
    author name string

    Identifiers

     
                      Retrieved from "https://www.wikidata.org/w/index.php?title=Q38453565&oldid=1966805275"